Medpace (MEDP) CEO reports open-market stock sales totaling 37,393 shares

Rhea-AI Filing Summary

August J. Troendle, CEO, director and reported 10% owner of Medpace Holdings, Inc. (MEDP), reported open-market sales of common stock executed pursuant to a limit order during an open window period. On 08/29/2025 he sold 36,196 shares at a weighted average price reported as $475.9, leaving 925,799 shares directly beneficially owned. On 09/02/2025 he sold 1,197 shares at a weighted average price reported as $475.11, leaving 924,602 shares directly owned. He also may be deemed to indirectly own 4,733,019 shares held by Medpace Investors, LLC, of which he is sole manager with voting and investment control. The form was signed by an attorney-in-fact on 09/03/2025.

Positive

• Continued significant indirect ownership of 4,733,019 shares via Medpace Investors, LLC indicates sustained control influence
• Disclosures specify sales were executed via limit orders during an open window, which aligns with standard insider trading windows

Negative

• Insider sold 37,393 shares across 08/29/2025 and 09/02/2025 at weighted average prices in the ~$475 range, reducing direct holdings
• Sales were not reported as part of a 10b5-1 plan, which may prompt investor questions about timing and intent

Insights

Securities Analyst

TL;DR: Insider sales were executed via limit orders during an open window; substantial indirect ownership remains material.

The reported sales total 37,393 shares executed across two dates at weighted average prices in the mid-$475 range. While these are sizable absolute sales, the reporting person retains significant direct and indirect holdings: 924,602 shares directly plus 4,733,019 shares indirectly via Medpace Investors, LLC. The transactions were disclosed as routine, effected during an open window and not pursuant to a 10b5-1 plan per the form. For market impact, these sales reduce direct stake modestly but do not materially alter control given MPI holdings. Impact rating: 0.

Corporate Governance Expert

TL;DR: CEO and 10% owner executed market sales but retains control through an investment vehicle; governance implications limited but noteworthy.

From a governance perspective, the CEO's sale of equity can prompt shareholder questions about insider views, yet the filing shows continued voting and investment control over a large block held by Medpace Investors, LLC. The disclosure includes the manager/sole controller designation and a disclaimer of beneficial ownership beyond pecuniary interest. Because control is preserved via MPI, these transactions raise limited governance concerns but merit investor attention to any future patterns of insider disposition. Impact rating: -1.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Troendle August J.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		S(1)		36,196	D	$475.9(2)	925,799	D
Common Stock	09/02/2025		S(1)		1,197	D	$475.11(3)	924,602	D
Common Stock								4,733,019	I	By Medpace Investors, LLC(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $475.00 to $477.11. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $475.00 to $475.70. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for August J. Troendle	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did August J. Troendle disclose for MEDP?

He disclosed open-market sales of 36,196 shares on 08/29/2025 and 1,197 shares on 09/02/2025, executed via limit orders.

How many MEDP shares does Troendle beneficially own after these transactions?

The filing reports 924,602 shares directly and an additional 4,733,019 shares indirectly through Medpace Investors, LLC.

At what prices were the MEDP shares sold?

The form reports weighted average prices: $475.9 for the 08/29/2025 sales and $475.11 for the 09/02/2025 sales; individual transaction prices ranged within the disclosed bands.

Does Troendle retain voting and investment control over MPI holdings?

Yes; the filing states he is the sole manager and controlling unit holder of Medpace Investors, LLC with sole voting and investment control.

When was this Form 4 filed/signed?

The signature on the form is dated 09/03/2025 by an attorney-in-fact for August J. Troendle.